Director of Public Prosecutions Issues Directive on PhysicianAssisted Death

first_imgNova Scotia’s Public Prosecution Service will not prosecute any physicians or members of a health-care team involved in a physician-assisted death so long as it falls within the scope of the Supreme Court of Canada’s 2015 Carter ruling on the issue, Director of Public Prosecutions Martin Herschorn said today, June 16. Mr. Herschorn issued the directive to Crown attorneys across the province. The directive remains in effect until the federal government passes its medical assistance in dying legislation. “We are in an unprecedented situation. In the absence of federal legislation, health-care professionals are concerned and this directive will provide clarity,” said Mr. Herschorn. “Crown attorneys will rely on this directive for guidance to ensure no prosecution of any health-care professional who has acted properly in a physician-assisted death.” The directive recognizes that the work of physicians, pharmacists, nurses and other regulated health-care professionals must be protected to ensure the constitutional right of patients wishing assisted death are safeguarded. The Public Prosecution Service consulted with police prior to issuing the directive. “This directive clearly outlines the procedure police agencies in Nova Scotia, including the RCMP, will follow until proper legislation is passed and it was developed with the understanding that the safety and security of Nova Scotians must remain the top priority,” said Chief Peter MacIsaac, president of the Nova Scotia Chiefs of Police Association. The Nova Scotia Public Prosecution Service was the first statutorily-based independent prosecution service in Canada. All prosecutions are the responsibility of the Director of Public Prosecutions. About 45,000 criminal code and 10,000 regulatory offence prosecutions are conducted annually by 90 Crown attorneys across the province. The Public Prosecution Service directive can be found at read more

Abbott Labs pleads guilty agrees to pay 15B for misbranding antiseizure drug

Abbott Labs pleads guilty, agrees to pay $1.5B for misbranding anti-seizure drug Depakote AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email WASHINGTON – Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.The case includes a criminal fine and forfeiture of $700 million and civil settlements with the federal government and states totalling $800 million. Deputy Attorney General James Cole said Monday the settlement reflects the determination by government “to hold accountable those who commit fraud.”At a news conference at the Justice Department, U.S. Attorney Timothy Heaphy said that the top levels of Abbott carried out a strategy of systematically marketing the drug for purposes other than what federal regulators had allowed.The illegal conduct was not the product of “some rogue sales representatives,” said Heaphy, the U.S. attorney for the western district of Virginia. He said the company engaged in the strategy from 1998 to at least 2006.Separately, Virginia Attorney General Ken Cuccinelli announced a $100 million settlement with Abbott of consumer claims in 45 states and the District of Columbia. The consumer claims over Abbott’s promotion of Depakote for unapproved uses were brought under the Virginia Consumer Protection Act.Depakote is an anti-seizure and mood-stabilizing drug prescribed for bipolar disorder.However, the company admitted that it marketed the drug for unapproved uses, including treatment of schizophrenia, agitated dementia and autism.The company admitted that it trained a specialized sales force to promote Depakote in treating dementia because the drug was not subject to federal regulations designed to prevent the use of unnecessary medications in nursing homes.The company also marketed Depakote to treat schizophrenia. Clinical trials failed to demonstrate that adding Depakote was any more effective than antipsychotic drugs in treating schizophrenia, according to court papers in the case.Under the care of a physician, patients are sometimes prescribed drugs for purposes not approved by the FDA. However, pharmaceutical companies cannot market drugs for unapproved purposes.Illinois-based Abbott said the company was pleased to resolve the matter. It said that it takes its responsibility to patients and health care providers seriously. Under the settlement, the company has agreed to enter a five-year probationary period designed to ensure that there is no repeat of the company’s misconduct.Reuben Guttman, an attorney whose whistleblower clients brought Abbott’s activities to the attention of government investigators, said that the case shows how a company elevated aggressive sales and marketing of Depakote over medical decision-making. Abbott, said Guttman, “violated basic norms of health care and ethics.” by News Staff Posted May 7, 2012 7:21 pm MDT read more